Navigation Links
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Date:12/8/2009

eristic of the drug to iron complex formation, confirming the expected 1:3 Fe(II)-drug ratio for both doxorubicin and mitoxantrone. In contrast, no spectrophotometric changes were observed with iron added to pixantrone, clearly demonstrating that pixantrone does not bind iron. In vitro studies using H2C9 rat myocardial cells indicate that pixantrone (ID50 >50 ug/ml) is far less toxic than doxorubicin (ID50= 1 ug/ml). Moreover, pixantrone does not induce significant reactive oxygen species (ROS) production in the H2C9 cells compared to doxorubicin.

About Pixantrone

Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class. Pixantrone has been granted fast track status designation.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, '/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
4. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
5. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
9. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 22. Mai 2013 Ranbaxy ... Tochtergesellschaft von Daiichi Sankyo Co., Ltd. ... 22. Mai die Maßnahmen bekannt, die ... hat, um sich der Angelegenheiten der ... http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html ). Daiichi Sankyo ...
(Date:5/22/2013)... May 22, 2013  Heska Corporation (NASDAQ: HSKA, "Heska" or ... products, announced today that the Company will present at the ... 2013 at the Le Parker Meridian hotel, 119 W. 56 ... . The presentation is scheduled to begin at 2:15 p.m. ... Heska Heska Corporation (NASDAQ: HSKA - ...
(Date:5/22/2013)... May 22, 2013  Team Health Holdings Inc. ("TeamHealth") ... suppliers of outsourced healthcare professional staffing and administrative services ... the United States , today announced that its ... Bank Healthcare Conference held on May 29, 2013 at ... 8:00 AM eastern time.  Interested investors and other parties ...
Breaking Medicine Technology:Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an 2Team Health Holdings Inc. to Present at the 38th Annual Deutsche Bank Healthcare Conference 2
... THE WOODLANDS, Texas , Jan. 25 In response ... York Times article, " Radiation Offers New Cures and Ways to ... patients and the general public understand that the benefits received from radiation therapy ... disease with help from the US Oncology physician network, and their loved ones, ...
... , , , MOUNTAIN VIEW, Calif. ... enrollment of its pivotal US study for the ArterX Vascular ... patients who were scheduled to receive a synthetic vascular graft ... applications involved the placement of arteriovenous dialysis access grafts, carotid ...
Cached Medicine Technology:Benefits from Radiation Therapy Outweigh Risks for Cancer Patients 2Benefits from Radiation Therapy Outweigh Risks for Cancer Patients 3Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study 2
(Date:5/23/2013)... Better Life Maids of Portland Oregon is putting on ... one of a kind green house cleaning service in the ... May 29th, and a soft opening scheduled for June 3rd, ... in Portland recently and will travel to St. Louis June ... really is a lot to take in" stated Heather Richardson. ...
(Date:5/23/2013)... 23, 2013 Footwear etc. is pleased to ... Collection of sandals containing cork footbeds. Known for its extremely ... good sales for many years, and with this new collection ... , Dansko Shoes and Sandals are renowned ... is no exception. Containing leather and patent leather uppers in ...
(Date:5/23/2013)... Long-Term Care Insurance shopping site LTC Tree has ... for Long Term Care Insurance are approved by insurance companies ... to buy a Long Term Care Insurance policy is an ... purchase protection are increasingly being turned away by insurance companies, ... variety of chronic conditions appear to be responsible for the ...
(Date:5/23/2013)... AttorneyOne.com, a recognized authority on law, ... providing expert opinion in view of the recent news ... to court documents, on March 5, 2013 a woman ... no. 3:2013cv50102) alleging that her husband suffered massive brain ... is mainly used as a blood thinner for patients ...
(Date:5/22/2013)... St. Petersburg, FL (PRWEB) May 23, 2013 ... rarely affects men due to several factors, including estrogen ... Cellulite is essentially toxins and fatty deposits stored and ... skin. "To diminish cellulite, one must take a multi-pronged ... These multi-pronged actions include: , Specific products like ...
Breaking Medicine News(10 mins):Health News:Better Life Maids of Portland Oregon Prepares For a Summer of 2013 Launch 2Health News:Footwear etc. Announces the New Collection of Dansko Cork Sandals 2Health News:More Baby Boomers Rejected by Long Term Care Insurance Companies 2Health News:More Baby Boomers Rejected by Long Term Care Insurance Companies 3Health News:New Lawsuit on Pradaxa Brain Hemorrhage: Now, AttorneyOne Can Provide Advice 2Health News:Get Cellulite Under Control Now with Cellulite Whisperer® Products Introduced by Sublime Beauty® 2
... H1N1 in a cat or pigs are likely very rare, experts ... news broke on Wednesday that a domestic cat had come down ... owners, many people no doubt wondered how vulnerable their own pets ... protecting from this strain of flu? The answer, experts say, is ...
... EF Johnson Technologies, Inc. (Nasdaq: EFJI ) ... results for the quarter ending September 30, 2009, and ... 4:30 p.m. Eastern Time on Thursday, November 12, 2009. ... Jana Ahlfinger Bell, executive vice president and chief financial ...
... , PURCHASE, N.Y., Nov. 4 Nutrition 21, Inc. ... ingredients and finished products under the Iceland Health®, Chromax®, ... sugar levels, improve cardiovascular health, enhance memory and reduce ... first quarter of fiscal year 2010 ended September 30, ...
... differently than Gardasil, Cervarix, it targets inside of virus, ... A vaccine that targets human papillomavirus (HPV) is able ... into full-blown malignancies, Dutch researchers report. , Two other ... for young women to prevent infection with HPV, which ...
... Inc. (Nasdaq: GHDX ) today reported financial results and business ... increased to $39.5 million in the third quarter of 2009 compared ... revenue from the Onco type DX® breast cancer test was ... 39 percent, compared with $28.1 million in the third quarter of ...
... Nov. 4 (HealthDay News) -- Eating too fast can lead ... hormones in the gut that trigger the feeling of being ... ate 300 milliliters of ice cream at different rates. Blood ... before and after consumption of the ice cream. Participants who ...
Cached Medicine News:Health News:Rest Easy. When It Comes to Swine Flu, Your Pet Is Safe 2Health News:Rest Easy. When It Comes to Swine Flu, Your Pet Is Safe 3Health News:EF Johnson Technologies, Inc. Announces Third Quarter Financial Reporting Date 2Health News:Nutrition 21 Announces Fiscal First Quarter 2010 Financial Results 2Health News:Nutrition 21 Announces Fiscal First Quarter 2010 Financial Results 3Health News:Nutrition 21 Announces Fiscal First Quarter 2010 Financial Results 4Health News:Nutrition 21 Announces Fiscal First Quarter 2010 Financial Results 5Health News:Nutrition 21 Announces Fiscal First Quarter 2010 Financial Results 6Health News:New HPV Vaccine Might Stop Vulvar Cancer in its Tracks 2Health News:New HPV Vaccine Might Stop Vulvar Cancer in its Tracks 3Health News:Genomic Health Announces Third Quarter 2009 Financial Results and Business Progress 2Health News:Genomic Health Announces Third Quarter 2009 Financial Results and Business Progress 3Health News:Genomic Health Announces Third Quarter 2009 Financial Results and Business Progress 4Health News:Genomic Health Announces Third Quarter 2009 Financial Results and Business Progress 5Health News:Genomic Health Announces Third Quarter 2009 Financial Results and Business Progress 6Health News:Genomic Health Announces Third Quarter 2009 Financial Results and Business Progress 7Health News:Genomic Health Announces Third Quarter 2009 Financial Results and Business Progress 8Health News:Genomic Health Announces Third Quarter 2009 Financial Results and Business Progress 9Health News:Fast Eating Limits Gut Hormones That Induce Fullness 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: